B-cell Malignancy clinical trials at University of California Health
2 research studies open to eligible people
Showing trials for
A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies
open to eligible people ages 18 years and up
Study consists of two main parts to explore BGB-16673 recommended dosing, a part 1 monotherapy dose finding comprised of monotherapy dose finding and monotherapy safety expansion of selected doses, and a part 2 (cohort expansion cohorts)
at UCLA
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
open to eligible people ages 18 years and up
This is an open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.
at UCSF
Last updated: